Loading... Please wait...
Sort by:
  • Biosimilars: European Payer Insights (2019)
    Learn More Biosimilars: European Payer Insights (2019)
    As the European biosimilars market surges, what do payers see as the next steps? The approval in 2018 of biosimilar versions of adalimumab (Abbvie's Humira) and trastuzumab (Roche's Herceptin) is a major boost to the...
  • Paying for Gene Therapy: Payer Insights
    Learn More Paying for Gene Therapy: Payer Insights
    Payers caution pharma to think hard about price if they want support for their gene therapies The message from payers is stark: developers who present gene therapies with limited clinical data, eye wateringly high...
  • Orphan Drugs: Drivers of Market Growth (2019)
    Learn More Orphan Drugs: Drivers of Market Growth (2019)
    Orphan drugs: Building your profits or draining your resources? Substantial growth prospects in orphan drugs (more than double the overall pharma market) have enticed many pharma companies to enter the fray. But all...
  • Trends in KOL Experience Management
    Learn More Trends in KOL Experience Management
    How well does your MSL KOL engagement activity compare to competitors? What tools are being used today to measure engagement with KOLs? How often are KOLs surveyed regarding satisfaction levels? Which metrics are...
  • KAM Metrics: Measuring Success (2019)
    Learn More KAM Metrics: Measuring Success (2019)
    Secure a successful future for your KAM teams by proving their true value KAM teams are still evolving but they're also concerned about their future. They need appropriate measures to demonstrate their true value...
  • Indication-level Pricing: Payer Insights
    Learn More Indication-level Pricing: Payer Insights
    Can pharma persuade payers of the benefits of indication-level pricing? Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good...
  • MSL Teams: Field Force size and structure (2019)
    Learn More MSL Teams: Field Force size and structure (2019)
    What factors determine the optimum MSL field-based team size and structure? How many brands should MSL field-based teams represent and what constitutes an acceptable territory? What educational background and...
  • Real World Data and Evidence: Payer Insights
    Learn More Real World Data and Evidence: Payer Insights
    Payers have great expectations for real world data. Is pharma meeting them? It's sink or swim time. Advancements in drug data collection methodologies and deeper understanding of what can be achieved has finally opened...
  • Review of Influence: The Institute for Clinical and Economic Review (ICER)
    Learn More Review of Influence: The Institute for Clinical and Economic Review (ICER)
    As the Institute for Clinical and Economic Review's (ICER) influence on payer behaviour and health policy grows, how should pharma respond? The ICER's novel and inclusive work on the value of drugs, using its own value...
  • The Impact of Drug Compounding on Pharma
    Learn More The Impact of Drug Compounding on Pharma
    Drug compounding meets unmet clinical needs, widens therapy choice and expands patient access to medicines. What are the lessons and opportunities for pharma? Drug compounding is a fast growing sector meeting the needs...
  • The Future of CRISPR
    Learn More The Future of CRISPR
    Where will CRISPR deliver real value? Investors and pharma are enthusiastic about CRISPR gene editing technology: not only can it be used to develop new therapeutics, it has become a powerful tool in drug discovery,...
  • Trends in Pharma-Patient Engagement
    Learn More Trends in Pharma-Patient Engagement
    Exactly how is Pharma organising and benefitting from its patient engagement strategy? How are patient engagement teams structured and resourced? When do teams engage with patients and what are the main...
  • Innovative drugs: Mapping the Pricing and Reimbursement Landscape
    Learn More Innovative drugs: Mapping the Pricing and Reimbursement Landscape
    Health Technology Assessment (HTA) reviews are shaping the competitive landscape for innovative drugs in non-US markets. Between January 2016 and June 2018, 95 innovative medicines were approved in the US–but only...
  • Trends in Digital Pharma Marketing
    Learn More Trends in Digital Pharma Marketing
    What are the trends and developments that will drive pharma's digital marketing initiatives? What are the trends that are shaping digital pharma marketing? How will increased investment be used to drive the digital...
  • Market Access Team Structure and Function – Industry Survey (2019)
    Learn More Market Access Team Structure and Function – Industry Survey (2019)
    How are market access teams developing to meet evolving stakeholder demands? What are the trends that are defining market access skills? Which core competencies should teams be developing for the future? What market...
  • Pharma-Tech Partnerships: Key Success Factors
    Learn More Pharma-Tech Partnerships: Key Success Factors
    What does an ideal Pharma-Tech partnership look like? Learn from Merck, Sanofi, Boehringer Ingelheim and UCB With tech companies making their presence felt in the health market and a demand for greater efficiency...

customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved